Ashwagandha Root Extract Spec: Ratio, Metals, COA

Buyer’s snapshot

USP sets ashwagandha root powder at not less than 0.3% withanolides and root dry extract at not less than 2.5%. Published surveys put total withanolides in the raw root at roughly 0.5% of dry weight or lower, which is the number that makes most extraction-ratio claims checkable.

A “10:1 standardized to 10% withanolides” spec implies a starting root at 1.0% withanolides. That sits above the commonly published ceiling, so the ratio, the assay, or the botanical part is doing work the spec does not disclose.

In October 2025 the Botanical Adulterants Prevention Program published a laboratory guidance document reviewing 22 analytical methods and called withanolide-only testing “inadequate and unsuitable” for detecting leaf and stem admixture in root material.

For a US SKU sold into California, the Proposition 65 lead level of 0.5 micrograms per day is roughly 3.6 times tighter than the EU finished-supplement limit at a 600 mg daily extract dose. Specify against the tighter one.

Silk Route Ventures supplies ashwagandha root material and manufactures capsules at Matale under BRCGS and FSSC 22000 V6, with a 50 kg per SKU raw-material MOQ and COA on every batch.

Most ashwagandha purchase specifications a supplier receives are three lines long: root extract, 10:1, 5% withanolides. Those three lines are not a specification. They are a price bracket. They leave the assay method unstated, the botanical part unverified, the heavy-metal ceiling undefined for the destination market, and the extraction ratio unreconciled against anything. This piece is for formulators who already have a calm-and-stress SKU on the roadmap and want the purchase spec and the batch COA to hold up when a retailer’s technical team asks how the numbers were arrived at.

The starting point is that ashwagandha is now a volume ingredient, not a specialty one. Precedence Research valued the global ashwagandha market at USD 837.5 million in 2025, rising to USD 915.4 million in 2026. Volume that size attracts economic adulteration, and the adulteration in this category is specific and well documented.

Does the extraction ratio reconcile with the withanolide claim?

A drug-to-extract ratio and a standardization percentage are two claims about the same batch, and they constrain each other. Divide the claimed withanolide percentage by the extraction ratio and the result is the minimum withanolide content the starting root must have carried. USP sets ashwagandha root powder at not less than 0.3% withanolides, calculated as the sum of withanolide aglycones and withanolide glycosides on the dried basis. Published analyses put total withanolides in the plant at roughly 0.5% of dry weight or lower. Anything that implies a starting root above about 1% deserves a question.

Claimed spec	Implied minimum withanolide content of the starting root	Reconciles?
10:1, 2.5% withanolides	0.25%	Yes, conservative
20:1, 10% withanolides	0.50%	Yes, at the published upper end
10:1, 5% withanolides	0.50%	Yes, at the published upper end
10:1, 10% withanolides	1.00%	Marginal, ask for the root assay
5:1, 10% withanolides	2.00%	No
4:1, 5% withanolides	1.25%	No

The arithmetic is deliberately generous. It assumes total recovery of withanolides into the extract, which no solvent process achieves, and it assumes the extract carries no maltodextrin or other carrier. Both assumptions push the real implied figure higher, not lower. So the number the division produces is a floor.

SRV finding: running this division across incoming supplier offers is the cheapest screening step available to a formulator, and it costs nothing. When a quoted ratio and a quoted percentage cannot both be true of the same root, one of four things is happening: the ratio is nominal rather than measured, the assay is a non-specific method reading more than withanolides, aerial parts have been blended in, or the extract has been fortified. Each of those has a different remedy, and the spec should be written to distinguish them before a purchase order exists.

That last point is where the specification earns its keep. Requiring the supplier to state the extraction ratio as a native ratio, before any carrier or excipient is added, converts a marketing number into a testable one. A native 10:1 with 10% added maltodextrin is not a 10:1 finished powder, and a spec that does not separate the two invites the ambiguity.

What identity testing has to sit alongside the withanolide assay?

Withanolides occur in ashwagandha leaves and stems as well as in the root, which is why a withanolide assay cannot by itself prove that a root extract is root. In October 2025 the Botanical Adulterants Prevention Program, the joint programme of the American Botanical Council, the American Herbal Pharmacopoeia and the National Center for Natural Products Research, published a laboratory guidance document on ashwagandha root reviewing 22 analytical methods. Its finding was blunt: test methods that only assess the presence of withanolides are, in the document’s words, “inadequate and unsuitable” for detecting undeclared aerial-part admixture. Stefan Gafner, chief science officer at the American Botanical Council, framed the document as a way for companies to catch adulterated material before purchase rather than after.

This is the single most consequential gap in a typical three-line ashwagandha spec. A certificate can read “root extract, 5% withanolides by HPLC,” every number can be accurate, and the material can still contain leaf and stem. Two additions close it. The first is an orthogonal identity method rather than a second potency method, chromatographic profiling or a chlorophyll screen that responds to green tissue the root does not contain. The second is a written botanical-part declaration in the purchase contract, naming Withania somnifera root, excluding leaf, stem and other aerial parts, and making the declaration a condition of acceptance rather than a description.

The trade press caught up with this in stages. The adulteration bulletin came first, in 2019. The laboratory guidance document followed six years later, in October 2025, once the ingredient had moved from specialty to mainstream volume and the incentive had grown with it. Formulators who wrote their ashwagandha spec in the intervening years almost certainly wrote it around potency alone, because that was the guidance available at the time. Those specs are now a revision behind, and the revision is a paragraph of text, not a new supplier.

For a fuller treatment of why the clinical evidence base and the regulatory posture both sit on root rather than leaf, see the root versus leaf breakdown for capsule formulators. For the assay-method side, on how two different “2.5% withanolides” figures can describe different materials, see the withanolide assay and dosage guide.

Setting heavy-metal limits at the ingredient level, not the finished dose

Regulation (EU) 2023/915 sets maximum levels for lead at 3.0 mg/kg, cadmium at 1.0 mg/kg and mercury at 0.10 mg/kg in food supplements. The detail that catches formulators out is the basis: those levels apply to the ready-to-use supplement, not to the individual raw material. A raw ashwagandha extract has no EU maximum of its own. The ingredient limit has to be back-calculated from the finished dose and the inclusion rate, and it belongs in the purchase spec because the supplier cannot infer it.

Work an example. A capsule delivers 600 mg of ashwagandha extract per daily dose in a 1,000 mg total fill, so the extract is 60% of the finished product by mass. If the extract were the only meaningful lead contributor, an extract at 5.0 mg/kg would still land the finished supplement at 3.0 mg/kg and comply in the EU. Nobody should specify to that ceiling, but that is where the arithmetic sits.

Now run the same SKU for California. The Proposition 65 maximum allowable dose level for lead as a reproductive toxicant is 0.5 micrograms per day. At 600 mg of extract per day, the entire daily dose can carry 0.5 micrograms of lead, which works out to roughly 0.83 mg/kg in the extract. That is about 3.6 times tighter than the EU-derived figure for the same product.

Buyer’s checklist: setting the ingredient-level metal limits

Fix the daily extract dose in milligrams and the extract’s share of the finished fill

Identify the binding jurisdiction, EU finished-supplement maxima or the Proposition 65 daily dose, whichever produces the lower number

Back-calculate the permitted extract concentration, then apply a safety margin rather than specifying at the ceiling

State the limit in the purchase spec as a numeric ceiling per element, not as “complies with applicable regulations”

Name the analytical method (ICP-MS is the working default) and require the method on the COA

Require lead, cadmium, mercury and arsenic as a four-element panel, per lot, not per shipment

The practical consequence is that a single ashwagandha extract specification cannot serve a US and an EU SKU at different dose levels without being written to the tightest case. Most formulators discover this at the point a Californian retailer asks for the calculation. Writing it at spec stage costs one paragraph. The same per-lot logic that applies here applies across botanical raw materials generally, which is covered in more depth in the guide to reading a heavy metal and pesticide COA.

Residual solvents, microbiology, and the rest of the panel

The extraction solvent determines which residual-solvent limits apply, and it is a specification line in its own right. Water and ethanol extractions fall under ICH Q3C Class 3, where residual amounts up to 50 mg per day, corresponding to 5,000 ppm, are accepted without further justification. Acetone is also Class 3. Methanol is Class 2 and carries a materially tighter limit. A spec that names the permitted solvent system, rather than leaving it to the supplier, prevents a Class 2 solvent arriving inside a Class 3 assumption.

The rest of the panel is unglamorous and rarely disputed once written down.

Spec snapshot: ashwagandha root extract purchase specification Botanical: Withania somnifera, root only, aerial parts excluded and declared Identity: orthogonal method beyond the withanolide assay, chromatographic profile or chlorophyll screen Assay: total withanolides, method named (HPLC), aglycone and glycoside basis stated Extraction ratio: native ratio, stated before carrier addition, carrier declared separately Solvent: permitted system named, residual solvents to ICH Q3C class limits Heavy metals: lead, cadmium, mercury, arsenic, back-calculated ceilings per element, ICP-MS Microbiology: total plate count, yeast and mould, plus absence of Salmonella and E. coli Pesticides: panel aligned to destination market MRLs Physical: loss on drying, particle size, bulk and tapped density, organoleptic Documentation: per-lot COA with methods and limits printed alongside results

Particle size and bulk density belong on that list for a practical reason rather than a safety one. Encapsulation weight variation is a fill-consistency problem before it is a potency problem, and a fine extract powder with an undeclared carrier behaves differently on a capsule filler than the sample did in a bench trial.

The COA clauses that make a specification enforceable

A specification without contractual clauses is a wish list. Four clauses turn it into an instrument, and none of them are unusual enough that a competent supplier will object.

The first is method declaration. The COA states the analytical method next to every result, because a number without a method is not comparable between lots or between suppliers. The second is a tolerance band. Each parameter carries an explicit accept range, so a marginal result is resolved by the document rather than by a phone call. The third is a retained sample: the supplier holds a sealed retention from each lot for a defined period, which is the only thing that makes a downstream dispute resolvable rather than arguable. The fourth is a verification right, allowing the buyer to send any lot to a third-party laboratory of their choosing, with a stated rule for who bears the cost when a result falls outside the agreed band.

Add a deviation protocol and the set is complete. It should say what happens when a lot misses: quarantine, notification within a defined window, and a written decision from the buyer before the material moves. Most supply relationships that break down over quality break down over the absence of that paragraph rather than over the failure itself.

How Silk Foods Ceylon handles ashwagandha ingredient supply and capsule manufacturing

Silk Route Ventures (SRV) supplies ashwagandha root material and finished capsules from the Silk Foods Ceylon (SFC) facility at Hapugasyaya in Nalanda, Matale, in the geographic centre of Sri Lanka. The site runs a 10,000 sq ft processing floor on a cellular manufacturing layout, which is what allows a 400-plus SKU range without a separate audit cycle per introduction.

Certification snapshot: Silk Foods Ceylon, Matale BRCGS (covers the spice, herb, coconut, plant-based and retorted product lines) FSSC 22000 V6 (covers the full processing scope, including encapsulation) USDA Organic and EU Organic (per SKU) Registered with the Sri Lanka Export Development Board and with Sri Lanka’s Department of Ayurveda; FDA-registered facility

The numbers a formulator needs at RFQ stage are these. Bulk raw-material MOQ is 50 kg per SKU on a first order, and the per-SKU basis matters: a six-botanical launch needs 50 kg of each, not 50 kg in total. Capsule contract manufacturing runs from 180 bottles per single shift, against a line capacity of 100,000 capsules per shift and 200,000 per day. Samples ship door to door by international courier at 3 to 5 business days. Production lead time from purchase order to dispatch is 2 to 3 weeks, with sea freight at 3 to 4 weeks to the EU and 4 to 5 weeks to the US. COA is issued on every batch, with third-party testing available against customer-specified parameters, which is the mechanism that carries the back-calculated metal ceilings described above onto an actual document.

Frequently asked questions

What withanolide percentage should an ashwagandha root extract be specified to?

USP sets ashwagandha root dry extract at not less than 2.5% withanolides on the dried basis, as the sum of withanolide aglycones and glycosides. Higher standardizations are available, but the spec should also name the assay method and state the extraction ratio, since a percentage alone does not identify the material.

How do I check whether an extraction ratio claim is plausible?

Divide the claimed withanolide percentage by the extraction ratio to get the minimum withanolide content implied for the starting root. USP sets root powder at not less than 0.3% withanolides, and published analyses put the plant near 0.5% of dry weight. An implied figure above roughly 1% warrants a root assay before purchase.

Is a withanolide assay enough to prove an extract is root only?

No. The Botanical Adulterants Prevention Program’s October 2025 laboratory guidance document, which reviewed 22 analytical methods, describes withanolide-only testing as inadequate for detecting leaf and stem admixture, because aerial parts contain withanolides too. Pair the assay with an orthogonal identity method and a written botanical-part declaration.

Which heavy-metal limit applies, the EU one or the US one?

Regulation (EU) 2023/915 sets 3.0 mg/kg lead in the finished supplement, while California’s Proposition 65 sets a 0.5 microgram daily dose for lead. At a 600 mg daily extract dose the Proposition 65 figure works out near 0.83 mg/kg in the extract, roughly 3.6 times tighter. Specify against whichever is lower for the destination market.

Does Silk Route Ventures supply bulk ashwagandha and manufacture private-label capsules?

Yes, both. Bulk root material ships against the buyer’s written spec at a 50 kg per SKU first-order MOQ, and capsule contract manufacturing starts at 180 bottles per single shift at the Matale facility, which holds BRCGS and FSSC 22000 V6. COA is issued per batch and samples ship by courier at 3 to 5 business days.

How Silk Route Ventures can help

Silk Route Ventures (SRV) manufactures nutraceutical capsules and supplies bulk Ayurvedic and functional botanicals to wellness brands globally. The Silk Foods Ceylon (SFC) facility holds BRCGS and FSSC 22000 V6 covering encapsulation, with USDA Organic and EU Organic on the relevant SKUs. Capsule MOQ is 180 bottles per single shift, bulk raw-material MOQ is 50 kg per SKU, and samples ship by international courier at 3 to 5 business days. For brands writing a first ashwagandha specification, the SRV team will review a draft spec against the parameters above and return a matched COA template alongside the quotation. Contact us to send an inquiry or request a sample.

Sources

United States Pharmacopeia, Ashwagandha Root Powder monograph (USP-NF), retrieved 2026-09-04, https://doi.usp.org/USPNF/USPNF_M2788_02_01.html
United States Pharmacopeia, Ashwagandha Root Dry Extract monograph (USP-NF), retrieved 2026-09-04, https://doi.usp.org/USPNF/USPNF_M2789_08_01.html
Botanical Adulterants Prevention Program (ABC, AHP and NCNPR), Ashwagandha Root Laboratory Guidance Document, October 2025, reported by Nutrition Insight, retrieved 2026-09-04, https://www.nutritioninsight.com/news/guidance-document-ashwagandha-root-adulteration-authentication.html
European Commission, Commission Regulation (EU) 2023/915 of 25 April 2023 on maximum levels for certain contaminants in food, retrieved 2026-09-04, https://eur-lex.europa.eu/eli/reg/2023/915/oj/eng
California Office of Environmental Health Hazard Assessment, Proposition 65 No Significant Risk Levels (NSRLs) and Maximum Allowable Dose Levels (MADLs), retrieved 2026-09-04, https://oehha.ca.gov/proposition-65/general-info/proposition-65-no-significant-risk-levels-nsrls-and-maximum-allowable-dose-levels-madls
International Council for Harmonisation, ICH Q3C (R9) Guideline for Residual Solvents, retrieved 2026-09-04, https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q3c-r9-guideline-impurities-guideline-residual-solvents-step-5_en.pdf
Precedence Research, Ashwagandha Market Size, Share and Trends 2026 to 2035, retrieved 2026-09-04, https://www.precedenceresearch.com/ashwagandha-market

Ashwagandha Root Extract Spec: Extraction Ratio, Metals, COA